{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:31:52Z","timestamp":1793770312577,"version":"4.6.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.lfs.2026.124739","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:56:45Z","timestamp":1791874605000},"page":"124739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Inhibition of the MEK-ERK signaling pathway reverses acquired osimertinib resistance in NSCLC attributed to AXL overexpression"],"prefix":"10.1016","volume":"406","author":[{"given":"Kai","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqian","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2026.124739_bb0005","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lfs.2026.124739_bb0010","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.molmed.2019.04.012","article-title":"Abandoning the notion of non-small cell lung cancer","volume":"25","author":"Relli","year":"2019","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.lfs.2026.124739_bb0015","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lfs.2026.124739_bb0020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.7888\/juoeh.41.153","article-title":"Treatment of non-small cell lung cancer with EGFR-mutations","volume":"41","author":"Yoneda","year":"2019","journal-title":"J. UOEH"},{"key":"10.1016\/j.lfs.2026.124739_bb0025","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11684-016-0488-1","article-title":"Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors","volume":"10","author":"Wang","year":"2016","journal-title":"Front. Med."},{"key":"10.1016\/j.lfs.2026.124739_bb0030","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/annonc\/mdy222","article-title":"Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer","volume":"30","author":"Ricordel","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lfs.2026.124739_bb0035","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2026.124739_bb0040","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.lfs.2026.124739_bb0045","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1158\/1078-0432.CCR-18-1542","article-title":"Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC","volume":"24","author":"Le","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2026.124739_bb0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lfs.2026.124739_bb0055","first-page":"5016","article-title":"axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase","volume":"11","author":"O'Bryan","year":"1991","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.lfs.2026.124739_bb0060","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41419-024-06493-0","article-title":"Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer","volume":"15","author":"Xie","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.lfs.2026.124739_bb0065","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/1078-0432.CCR-07-0862","article-title":"Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme","volume":"14","author":"Hutterer","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2026.124739_bb0070","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2013-03-491431","article-title":"Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma","volume":"122","author":"Ben-Batalla","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2026.124739_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154186","article-title":"Clinical, pathological, and molecular features of lung adenocarcinomas with AXL expression","volume":"11","author":"Sato","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2026.124739_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101649","article-title":"AXL is a driver of stemness in normal mammary gland and breast cancer","volume":"23","author":"Engelsen","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.lfs.2026.124739_bb0085","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lfs.2026.124739_bb0090","first-page":"1","article-title":"Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer","volume":"6","author":"Hart","year":"2013","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.lfs.2026.124739_bb0095","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/carcin\/bgt372","article-title":"Gas6\/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma","volume":"35","author":"Lee","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.lfs.2026.124739_bb0100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13045-019-0834-2","article-title":"First-in-human phase I study of BPI-9016M, a dual MET\/Axl inhibitor, in patients with non-small cell lung cancer","volume":"13","author":"Hu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lfs.2026.124739_bb0105","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2026.124739_bb0110","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2026.124739_bb0115","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/onc.2012.89","article-title":"The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target","volume":"32","author":"Paccez","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.lfs.2026.124739_bb0120","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1158\/1541-7786.MCR-16-0350","article-title":"Phosphatidylserine sensing by TAM receptors regulates AKT-dependent chemoresistance and PD-L1 expression","volume":"15","author":"Kasikara","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.lfs.2026.124739_bb0125","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1158\/1078-0432.CCR-16-2586","article-title":"Integrative analysis identifies a novel AXL-PI3 kinase-PD-L1 signaling axis associated with radiation resistance in head and neck cancer","volume":"23","author":"Skinner","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2026.124739_bb0130","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1158\/0008-5472.CAN-14-0294","article-title":"AXL mediates resistance to cetuximab therapy","volume":"74","author":"Brand","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2026.124739_bb0135","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1158\/1078-0432.CCR-19-2321","article-title":"ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer","volume":"26","author":"Okura","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2026.124739_bb0140","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41419-019-1601-6","article-title":"AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells","volume":"10","author":"Kim","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.lfs.2026.124739_bb0145","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2026.124739_bb0150","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/bjc.2016.428","article-title":"Giving AXL the axe: targeting AXL in human malignancy","volume":"116","author":"Gay","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2026.124739_bb0155","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lfs.2026.124739_bb0160","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.lfs.2026.124739_bb0165","first-page":"67","article-title":"Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review","volume":"4","author":"Stewart","year":"2015","journal-title":"Transl. Lung Cancer Res."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320526005485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320526005485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:19:25Z","timestamp":1793769565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320526005485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":33,"alternative-id":["S0024320526005485"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124739","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of the MEK-ERK signaling pathway reverses acquired osimertinib resistance in NSCLC attributed to AXL overexpression","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124739","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"124739"}}